

DRAFT AGENDA

Alliance for Clinical Trials in Oncology
November 7, 2018
Lowes Chicago O'Hare Hotel
Rosemont, IL
10:00-1:00
Room: TBD

Respiratory Committee

Chair: Tom Stinchcombe, M.D.
Vice-Chairs: Dennis Wigle (Surgery)
Steven Schild (Radiation Oncology)
Stephen Graziano (Correlative Science)

1. Committee overview, and protocol accrual – Chair and Xiaofei Wang

2. Concepts in development

1. Brain metastases in mutation negative patients: chemotherapy + pembrolizumab

Mark Awad

2. Extensive stage SCLC- Jacob Sands

3. Lurbinecten in maintenance trial in ES-SCLC Jeff Petty

4. Colchicine Anti-inflammatory Tumor Outcomes Study – Early Lung Cancer

(CANTOS-ELC): A Randomized Double-Blind Placebo Controlled Trial of Adjuvant Colchicine for Non-Metastatic Stage 1A2, IA3, and IB Lung Cancer

3. NCI Lung-MAP Jyoti Patel

1. Entinostat + pembrolizumab- Jyoti Patel

2. Randomized Phase Ib/II Study of Docetaxel and CB-839 vs Docetaxel ± Ramucirumab in Patients with NSCLC Harboring KRAS and Co-Occurring Mutations in LKB1 or KEAP1 Genes or Both Muhammad Furqan

3. Mesothelioma–Robert Kratzke, Hedy Kindler, Arkadiusz Dudek

4. Correlative Science- Robert Kratzke, Stephen Graziano

5. Stage IV Non-Small Cell Lung Cancer

DRAFT AGENDA

1. **A221504** - Peripheral Opioid Receptor Antagonist in NSCLC – Pankaj Gupta,
Lyudmila Bazhenova
2. **AFT-42**: Nivolumab for patients with compromised organ function – Becca
Heist, Phil Stella
6. **Stage III Non-Small Cell Lung Cancer**
 1. **AFT-16**: Induction PDL-1 inhibition – Helen Ross, Jim Urbanic
 2. **AFT-46**: Chemo-immunotherapy for operable stage III NSCLC Linda Martin,
Jyoti Patel
7. **Early Stage Non-Small Cell Lung Cancer and Surgical Studies- Dennis Wigle**
 1. **A151216/081105- ALCHEMIST**- Personalized Adjuvant Therapy in Patients with
Completely Resected Non-Small Cell Lung Cancer – Geoffrey Oxnard,
Ramaswamy Govindan, Dennis Wigle, Sumithra Mandrekar
 2. **Adjuvant chemotherapy alone or in combination with pembrolizumab-**
Jacob Sands
8. **Small Cell Lung Cancer**
 1. **CALGB 30610**: Limited Stage Intergroup Trial– Jeffrey Bogart and Greg Masters
 2. **NRG 003**: ChemoRT +/- atezolizumab- Helen Ross
9. **Intergroup trials**
 1. **SWOG/NRG S1914: trial of immunotherapy followed by SBRT
followed by immunotherapy** Apar Ganti
 2. **SWOG/Alliance S1827** : PCI vs observation in ES-SCLC
 2. **EGFR transformed SCLC-** Vini Ernani
 3. **E5142** Erin Bertino
 4. **ALK biomarker trial-** Tom Stinchcombe
10. **Ongoing projects from other committees**

DRAFT AGENDA

October 22, 2019